William Spielfogel, DPM
Foot & Ankle Surgery · Brooklyn, NYNPI 1790767093
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,483 of the $11,283 with a category attached, or 75.2%. It is spread thinly across 39 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,399 and has fallen 72.5% since, to $1,210 in 2025.
Across 123 payments — averaging $91.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Royal Biologics, Inc.$2K
- Stryker$1K
- Gotham Surgical Solutions & Devices, Inc.$1K
- Acera Surgical, Inc.$862
- Smith+Nephew$708
- Polynovo North America LLC$526
- plus $5K from 33 others
Across 7 payments — averaging $14,286 each. An ownership or investment interest held by the physician or an immediate family member.
- Gramercy Extremity Orthopedics LLC$100K
What the payments were for
- Consulting fees$1,60014%
- Food & beverage$8,48375%
- Education$1,20011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Royal Biologics, Inc. | 7 | $1,902 |
| Stryker(2 entities) | 17 | $1,243 |
| Gotham Surgical Solutions & Devices, Inc. | 1 | $1,200 |
| Acera Surgical, Inc. | 6 | $862 |
| Smith+Nephew | 16 | $708 |
| Polynovo North America LLC | 3 | $526 |
| Zimmer Biomet | 4 | $447 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $432 |
| Medshape, Inc. | 4 | $410 |
| Heron Therapeutics, Inc. | 3 | $361 |
| Gramercy Extremity Orthopedics LLC | 1 | $317 |
| Reddress USA, Inc. | 2 | $296 |
| Novastep Inc. | 2 | $263 |
| Treace Medical Concepts, Inc. | 2 | $214 |
| Integra Lifesciences Corporation | 4 | $196 |
| Kerecis Limited | 2 | $192 |
| Amgen | 3 | $180 |
| Abbott | 1 | $168 |
| GRT US Holding, Inc. | 4 | $163 |
| Encore Medical, LP | 1 | $151 |
| Forma Medical | 1 | $126 |
| Medtronic | 1 | $121 |
| Bioventus LLC | 1 | $120 |
| Merck | 5 | $79 |
| Misonix Inc | 1 | $70 |
| Paratek Pharmaceuticals, Inc. | 4 | $65 |
| Ossio Inc | 1 | $64 |
| Nevro Corp. | 2 | $47 |
| Acell, Inc. | 2 | $46 |
| Sebela Pharmaceuticals Inc. | 2 | $46 |
| Orthofix Medical, Inc. | 1 | $44 |
| Baxter Healthcare | 1 | $40 |
| Organogenesis Inc. | 1 | $36 |
| Polarityte, Inc. | 2 | $33 |
| Nabriva Therapeutics, PLC | 2 | $29 |
| Alfasigma USA, Inc. | 1 | $27 |
| Sanara Medtech Inc. | 1 | $23 |
| Osiris Therapeutics Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fibrinet$1,600
- Restrata Wound Matrix$862
- Kerecis Omega3 SurgiClose$544
- Novosorb BTM$526
- Zynrelef$361
- ORTHOLOC 3DI$290
- DynaNail Helix, Washer, 15 mm$288
- JUBLIA$237
- Stravix$209
- Grafix PL PRIME$209
- A.L.P.S.$192
- Kerecis Omega3 GraftGuide$181
- Kerecis Omega3 Marigen$181
- PROSTEP MICA$172
- GRAVITY$172
- BIOskin$172
- VARIAX$172
- PROCLAIM$168
- DART-FIRE$163
- PECAPLASTY$158
How this compares
$11,283 in reported general payments places this provider in the 85th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 25 | $10,380 |
| Ketoconazole | 88 | $4,613 |
| Cephalexin | 34 | $1,342 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 16 | $1,064 |
| Ammonium Lactate | 50 | $888 |
| Mupirocin | 49 | $504 |
| Terbinafine Hcl | 64 | $497 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $165 |
| Clotrimazole | 13 | $154 |
| Methylprednisolone | 16 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $708 | $10,38025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 foot & ankle surgery providers in New York.
Other foot & ankle surgery in Brooklyn
- Yury RotshteynBrooklyn$43K
- Mario VoloshinBrooklyn$33K
- Bryan MakowerBrooklyn$28K
- Amit GandhiBrooklyn$21K
- Edward AzarBrooklyn$18K
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.